Nervenheilkunde 2020; 39(10): 663-669
DOI: 10.1055/a-1238-7891
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Therapie der intrazerebralen und subarachnoidalen Blutung

Therapy of intracerebral and subarachnoid hemorrhage
Maximilian I. Sprügel
1   Neurologische Klinik, Universitätsklinikum Erlangen
,
Hagen B. Huttner
1   Neurologische Klinik, Universitätsklinikum Erlangen
,
Stefan T. Gerner
1   Neurologische Klinik, Universitätsklinikum Erlangen
› Author Affiliations
Further Information

Publication History

Publication Date:
09 October 2020 (online)

ZUSAMMENFASSUNG

In den letzten Jahren gab es deutliche Fortschritte in der Akutbehandlung von Patienten mit intrazerebraler Blutung (ICB) und Subarachnoidalblutung (SAB). Allerdings sind die Letalität weiterhin hoch und das funktionelle Outcome der Überlebenden oft stark eingeschränkt. Während bei der ICB aufgrund des Parenchymdefekts häufig motorische Einschränkungen im Vordergrund stehen, leiden SAB-Patienten auch an alltagsrelevanten Folgeschäden wie Kopfschmerzen, Depressionen und kognitiven Einschränkungen. Bei der Behandlung der ICB stehen die Vermeidung einer frühen Blutungsprogression durch Blutdruckmanagement und Hämostase im Vordergrund sowie die Erprobung neuerer minimal-invasiver Techniken zur Blutungsausräumung. Weiterhin eine Herausforderung stellt das Management des Perifokalödems, des Hirndrucks, des Ventrikeleinbruchs und Hydrozephalus sowie die langfristige antithrombotische Therapie dar. Bei der SAB steht die zügige Aneurysmaausschaltung und Hydrozephalusbehandlung im Fokus der Akuttherapie. Neue Aspekte haben sich auch bei der Vermeidung und Behandlung von Vasospamen und sekundären zerebralen Ischämien ergeben. Weitere Forschungsfelder sind das optimale Drainagemanagement, mittels Ventrikel- und Lumbaldrainagen, sowie die intraventrikuläre Fibrinolyse. Die vorliegende Übersichtsarbeit geht auf diese relevanten Themenkomplexe in der Akut- und Langzeittherapie von ICB- und SAB-Patienten ein und gibt einen Überblick zu der aktuellen Datenlage und Kontroversen in diesen Behandlungsfeldern.

ABSTRACT

In recent years there have been significant advances in the acute treatment of patients with intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH). However, mortality remains high and functional outcome of surviving patients is often severely impaired. While ICH patients often suffer from motor deficits, SAH patients may be limited in daily activities due to concentration disorders, headaches, depression and cognitive impairment. Treatment of ICH focuses on prevention of early hematoma expansion by blood pressure management and hemostasis. Further, novel minimally invasive techniques for hemorrhage evacuation are currently at trial. The management of perihemorrhagic edema, intracranial pressure, ventricular involvement and hydrocephalus as well as long-term antithrombotic therapy remain challenging. In SAH, acute treatment relies on rapid aneurysm closure and hydrocephalus treatment. New aspects have also emerged in the prevention and treatment of vasospasms and secondary cerebral ischemia. Further research areas are optimal drainage management using ventricular and lumbar drains as well as intraventricular fibrinolysis. This review article deals with these relevant topics in acute and long-term treatment of ICH and SAH patients and provides an overview of current evidence and controversies in these treatment fields.

 
  • Literatur

  • 1 Sembill JA, Huttner HB, Kuramatsu JB. Impact of Recent Studies for the Treatment of Intracerebral Hemorrhage. Curr Neurol Neurosci Rep 2018; 18 (10) 71
  • 2 Moullaali TJ, Wang X, Martin RH. et al Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurol 2019; 18 (09) 857-64
  • 3 Buletko AB, Thacker T, Cho SM. et al Cerebral ischemia and deterioration with lower blood pressure target in intracerebral hemorrhage. Neurology 2018; 91 (11) e1058-e66
  • 4 Flibotte JJ, Hagan N, O’Donnell J. et al Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004; 63 (06) 1059-64
  • 5 Kuramatsu JB, Gerner ST, Schellinger PD. et al Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA 2015; 313 (08) 824-36
  • 6 Steiner T, Poli S, Griebe M. et al Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016; 15 (06) 566-73
  • 7 Pollack Jr CV, Reilly PA, van Ryn J. et al Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. N Engl J Med 2017; 377 (05) 431-41
  • 8 Connolly SJ, Crowther M, Eikelboom JW. et al Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2019; 7: 10
  • 9 Gerner ST, Kuramatsu JB, Sembill JA. et al Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol 2018; 83 (01) 186-96
  • 10 Mayer SA, Brun NC, Begtrup K. et al Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358 (20) 2127-37
  • 11 Baharoglu MI, Cordonnier C, Al-Shahi Salman R. et al Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016; 387 10038 2605-13
  • 12 Sprigg N, Flaherty K, Appleton JP. et al Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet 2018; 391 10135 2107-15
  • 13 Sprugel MI, Kuramatsu JB, Gerner ST. et al Antiplatelet Therapy in Primary Spontaneous and Oral Anticoagulation-Associated Intracerebral Hemorrhage. Stroke 2018; 49 (11) 2621-9
  • 14 Mendelow AD, Gregson BA, Rowan EN. et al Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial. Lancet 2013; 382 9890 397-408
  • 15 Kuramatsu JB, Biffi A, Gerner ST. et al Association of Surgical Hematoma Evacuation vs Conservative Treatment With Functional Outcome in Patients With Cerebellar Intracerebral Hemorrhage. JAMA 2019; 322 (14) 1392-403
  • 16 Hanley DF, Lane K, McBee N. et al Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial. Lancet 2017; 389 10069 603-11
  • 17 Roeder SS, Sprügel MI, Sembill JA. et al Influence of the Extent of Intraventricular Hemorrhage on Functional Outcome and Mortality in Intracerebral Hemorrhage. Cerebrovasc Dis 2019; 47 5–6 245-52
  • 18 Staykov D, Kuramatsu JB, Bardutzky J. et al Efficacy and safety of combined intraventricular fibrinolysis with lumbar drainage for prevention of permanent shunt dependency after intracerebral hemorrhage with severe ventricular involvement: A randomized trial and individual patient data meta-analysis. Ann Neurol 2017; 81 (01) 93-103
  • 19 Volbers B, Giede-Jeppe A, Gerner ST. et al Peak perihemorrhagic edema correlates with functional outcome in intracerebral hemorrhage. Neurology 2018; 90 (12) e1005-e12
  • 20 Sprügel MI, Kuramatsu JB, Volbers B. et al Perihemorrhagic edema: Revisiting hematoma volume, location and surface. Neurology 2019; 93 (12) e1159-e1170
  • 21 Bobinger T, Manaenko A, Burkardt P. et al Siponimod (BAF-312) attenuates perihemorrhagic edema and improves survival in experimental intracerebral haemorrhage. Stroke 2019; 50 (11) 3246-3254
  • 22 Hervella P, Rodríguez-Yáñez M, Pumar JM. et al Antihyperthermic treatment decreases perihematomal hypodensity. Neurology 2020; 94 (16) e1738-e48
  • 23 Steiner T, Al-Shahi Salman R. et al European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. International Journal of Stroke 2014; 9 (07) 840-55
  • 24 Sprügel MI, Sembill JA, Kuramatsu JB. et al Heparin for prophylaxis of venous thromboembolism in intracerebral haemorrhage. Journal of Neurology 2019: jnnp-2018-319786
  • 25 Biffi A, Kuramatsu JB, Leasure A. et al Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage. Ann Neurol 2017; 82 (05) 755-65
  • 26 Kuramatsu JB, Sembill JA, Gerner ST. et al Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J 2018; 39 (19) 1709-23
  • 27 Korompoki E, Filippidis FT, Nielsen PB. et al Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology 2017; 89 (07) 687-96
  • 28 van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007; 369 9558 306-18
  • 29 Connolly ES, Rabinstein AA, Carhuapoma JR. et al Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. Stroke 2012; 43 (06) 1711-37
  • 30 Steiner T, Juvela S, Unterberg A. et al European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis 2013; 35 (02) 93-112
  • 31 Bardach NS, Zhao S, Gress DR. et al Association between subarachnoid hemorrhage outcomes and number of cases treated at California hospitals. Stroke 2002; 33 (07) 1851-6
  • 32 Pandey AS, Gemmete JJ, Wilson TJ. et al High Subarachnoid Hemorrhage Patient Volume Associa With Lower Mortality and Better Outcomes. Neurosurgery 2015; 77 (03) 462-70
  • 33 Gerner ST, Huttner HB. Patients on NOACs in the Emergency Room. Curr Neurol Neurosci Rep 2019; 19 (07) 40
  • 34 Anker-Møller T, Troldborg A, Sunde N. et al Evidence for the Use of Tranexamic Acid in Subarachnoid and Subdural Hemorrhage: A Systematic Review. Semin Thromb Hemost 2017; 43 (07) 750-8
  • 35 Frontera JA, Fernandez A, Claassen J. et al Hyperglycemia After SAH. Stroke 2006; 37 (01) 199-203
  • 36 Oliveira-Filho J, Ezzeddine MA, Segal AZ. et al Fever in subarachnoid hemorrhage: relationship to vasospasm and outcome. Neurology 2001; 56 (10) 1299-304
  • 37 Lanzino G, D’Urso PI, Suarez J. The Participants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H. Seizures and Anticonvulsants after Aneurysmal Subarachnoid Hemorrhage. Neurocritical Care 2011; 15 (02) 247
  • 38 Huttunen J, Kurki MI, von und zu Fraunberg M. et al Epilepsy after aneurysmal subarachnoid hemorrhage. A population-based, long-term follow-up study. Neurology 2015; 84 (22) 2229-37
  • 39 Gerner ST, Reichl J, Custal C. et al Long-Term Complications and Influence on Outcome in Patients Surviving Spontaneous Subarachnoid Hemorrhage. Cerebrovascular Diseases 2020; 49 (03) 307-315
  • 40 Panczykowski D, Pease M, Zhao Y. et al Prophylactic Antiepileptics and Seizure Incidence Following Subarachnoid Hemorrhage: A Propensity Score-Matched Analysis. Stroke 2016; 47 (07) 1754-60
  • 41 Starke RM, Connolly Jr ES. Rebleeding after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2011; 15 (02) 241-6
  • 42 Arthur AS, Molyneux A, Coon AL. et al The safety and effectiveness of the Woven EndoBridge (WEB) system for the treatment of wide-necked bifurcation aneurysms: final 12-month results of the pivotal WEB Intrasaccular Therapy (WEB-IT) Study. Journal of NeuroInterventional Surgery 2019; 11 (09) 924-30
  • 43 Briganti F, Leone G, Marseglia M. et al Endovascular treatment of cerebral aneurysms using flow-diverter devices: A systematic review. Neuroradiol J 2015; 28 (04) 365-75
  • 44 Brinjikji W, Murad MH, Lanzino G. et al Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis. Stroke 2013; 44 (02) 442-7
  • 45 Spetzler RF, McDougall CG, Zabramski JM. et al The Barrow Ruptured Aneurysm Trial: 6-year results. J Neurosurg 2015; 123 (03) 609-17
  • 46 Molyneux AJ, Kerr RS, Yu LM. et al International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet 2005; 366 9488 809-17
  • 47 Molyneux AJ, Birks J, Clarke A. et al The durability of endovascular coiling versus neurosurgical clipping of ruptured cerebral aneurysms: 18 year follow-up of the UK cohort of the International Subarachnoid Aneurysm Trial (ISAT). The Lancet 2015; 385 9969 691-7
  • 48 Macdonald RL, Schweizer TA. Spontaneous subarachnoid haemorrhage. The Lancet 2017; 389 10069 655-66
  • 49 Lai L, Morgan MK. Predictors of in-hospital shunt-dependent hydrocephalus following rupture of cerebral aneurysms. J Clin Neurosci 2013; 20 (08) 1134-8
  • 50 Lu X, Ji C, Wu J, You W. et al Intrathecal Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage: Evidence From Randomized Controlled Trials and Cohort Studies. Front Neurol 2019; 10: 885
  • 51 Gerner ST, Kuramatsu JB, Abel H. et al Intraventricular fibrinolysis has no effects on shunt dependency and functional outcome in endovascular-treated aneurysmal SAH. Neurocrit Care 2014; 21 (03) 435-43
  • 52 Gaberel T, Gakuba C, Fournel F. et al FIVHeMA: Intraventricular fibrinolysis versus external ventricular drainage alone in aneurysmal subarachnoid hemorrhage: A randomized controlled trial. Neurochirurgie 2019; 65 (01) 14-9
  • 53 Bardutzky J, Witsch J, Jüttler E. et al EARLYDRAIN- outcome after early lumbar CSF-drainage in aneurysmal subarachnoid hemorrhage: study protocol for a randomized controlled trial. Trials 2011; 12: 203
  • 54 Al-Tamimi YZ, Bhargava D, Feltbower RG. et al Lumbar Drainage of Cerebrospinal Fluid After Aneurysmal Subarachnoid Hemorrhage. Stroke 2012; 43 (03) 677-82
  • 55 Blackburn SL, Grande AW, Swisher CB. et al Prospective Trial of Cerebrospinal Fluid Filtration After Aneurysmal Subarachnoid Hemorrhage via Lumbar Catheter (PILLAR). Stroke 2019; 50 (09) 2558-61
  • 56 Dorfer C, Frick A, Knosp E. et al Decompressive hemicraniectomy after aneurysmal subarachnoid hemorrhage. World Neurosurg 2010; 74 4–5 465-71
  • 57 Schirmer CM, Hoit DA, Malek AM. Decompressive Hemicraniectomy for the Treatment of Intractable Intracranial Hypertension After Aneurysmal Subarachnoid Hemorrhage. Stroke 2007; 38 (03) 987-92
  • 58 Reyes Kdl, Patel A, Bederson JB. et al Management of subarachnoid hemorrhage with intracerebral hematoma: clipping and clot evacuation versus coil embolization followed by clot evacuation. Journal of NeuroInterventional Surgery 2013; 5 (02) 99-103
  • 59 Wan A, Jaja BN, Schweizer TA. et al Clinical characteristics and outcome of aneurysmal subarachnoid hemorrhage with intracerebral hematoma. J Neurosurg 2016; 125 (06) 1344-51
  • 60 Macdonald RL, Higashida RT, Keller E. et al Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). The Lancet Neurology 2011; 10 (07) 618-25
  • 61 Dorhout Mees SM, Algra A, Vandertop WP. et al Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet 2012; 380 9836 44-9
  • 62 Kirkpatrick PJ, Turner CL, Smith C. et al Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. The Lancet Neurology 2014; 13 (07) 666-75
  • 63 Dorhout Mees SM, Rinkel GJ, Feigin VL. et al Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2007; 2007 (03) Cd000277
  • 64 Carlson AP, Hänggi D, Wong GK. et al Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage. Stroke 2020; 51 (04) 1142-9
  • 65 Kuramatsu JB, Kollmar R, Gerner ST. et al Is Hypothermia Helpful in Severe Subarachnoid Hemorrhage? An Exploratory Study on Macro Vascular Spasm, Delayed Cerebral Infarction and Functional Outcome after Prolonged Hypothermia. Cerebrovasc Dis 2015; 40 5–6 228-35
  • 66 Dankbaar JW, Slooter AJ, Rinkel GJ. et al Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. Crit Care 2010; 14 (01) R23-R
  • 67 Gathier CS, van den Bergh WM, van der Jagt M. et al Induced Hypertension for Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Randomized Clinical Trial. Stroke 2018; 49 (01) 76-83
  • 68 Jabbarli R, Pierscianek D, Rölz R. et al Endovascular treatment of cerebral vasospasm after subarachnoid hemorrhage. More is more. Neurology 2019; 93 (05) e458-e66
  • 69 Zwienenberg-Lee M, Hartman J. et al Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke 2008; 39 (06) 1759-65
  • 70 Sayama CM, Liu JK, Couldwell WT. Update on endovascular therapies for cerebral vasospasm induced by aneurysmal subarachnoid hemorrhage. 2006; 21 (03) 1